EGFR and lung carcinoma: Because of the inevitable drug resistance problems, other “molecular surgeries” using CRISPR technology to directly correct or disrupt the mutated site to inactivate the oncogenic activity, might be a more permanent strategy for EGFR-mutant lung cancer treatment.67 The CRISPR technology is poised to open the door to effective personalized cancer treatment from specific applications of genome screening to therapeutic strategies.68